Investigation of a new injectable thermosensitive hydrogel loading solid lipid nanoparticles

被引:21
作者
Guo, Xinhong [1 ,2 ]
Cui, Fude [1 ]
Xing, Yabing [2 ]
Mei, Qian [2 ]
Zhang, Zhenzhong [2 ]
机构
[1] Shenyang Pharmaceut Univ, Dept Pharmaceut Sci, Shenyang 110016, Peoples R China
[2] Zhengzhou Univ, Sch Pharm, Zhengzhou, Peoples R China
来源
PHARMAZIE | 2011年 / 66卷 / 12期
关键词
CONTROLLED-RELEASE; ANTICANCER DRUGS; RESISTANCE; DELIVERY; LIPOSOMES; CHEMOTHERAPY; COPOLYMERS; MECHANISMS; GEL;
D O I
10.1691/ph.2011.1070
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
For improving the effectiveness of cancer chemotherapy and avoiding rapid clearance of solid lipid nonoparticles (SLN) from the systemic circulation following systemic administration, 2-methoxyestradiol (2-ME) as model drug, PLGA-PEG-PLGA as hydrogel material, an injectable SLN loaded hydrogel was developed. Integrity of SLN within and released from the hydrogel was confirmed by direct visualization by a scanning electron microscope (SEM), particle size measurement by laser light scattering, and free drug concentration in the release medium by ultracentrifugation. Moreover, in vitro release, thermo-sensitive properties and rheological behavior were investigated. The results indicated that SLN were stable in the hydrogel. In the release medium, most 2-ME existed in the SLN and intact 2-ME SLN could be released from the hydrogel for a prolonged period over 46 days. Their concentration showed a significant effect on the release rate, in contrast to particle size and pH value of the release medium. In addition, the SLN loaded hydrogel could still exhibit reversible thermo-sensitive properties and better syringeability. These results suggested that the SLN loaded hydrogel could transport SLN to the target site and control prolonged release of SLN, which may increase the efficacy of cancer chemotherapy.
引用
收藏
页码:948 / 952
页数:5
相关论文
共 21 条
[1]   Drug resistance reversal - are we getting closer? [J].
Baird, RD ;
Kaye, SB .
EUROPEAN JOURNAL OF CANCER, 2003, 39 (17) :2450-2461
[2]   Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy [J].
Bhattacharya, A ;
Tóth, K ;
Mazurchuk, R ;
Spernyak, JA ;
Siocum, HK ;
Pendyala, L ;
Azrak, R ;
Cao, SS ;
Durrani, FA ;
Rustum, YM .
CLINICAL CANCER RESEARCH, 2004, 10 (23) :8005-8017
[3]   Liposomes dispersed within a thermosensitive gel: A new dosage form for ocular delivery of oligonucleotides [J].
Bochot, A ;
Fattal, E ;
Gulik, A ;
Couarraze, G ;
Couvreur, P .
PHARMACEUTICAL RESEARCH, 1998, 15 (09) :1364-1369
[4]   Fabrication and characterizations of a novel drug delivery device liposomes-in-microsphere (LIM) [J].
Feng, SS ;
Ruan, G ;
Li, QT .
BIOMATERIALS, 2004, 25 (21) :5181-5189
[5]   Resistance mechanisms of gastrointestinal cancers: why does conventional chemotherapy fail? [J].
Gieseler, F ;
Rudolph, P ;
Kloeppel, G ;
Foelsch, UR .
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2003, 18 (06) :470-480
[6]   An investigation on intestinal absorption of a new anticancer drug, 2-methoxyestradiol [J].
Guo, Xin-Hong ;
Zhang, Nan ;
Cui, Fu-De ;
Du, Bin ;
Zhang, Zhen-Zhong .
PHARMAZIE, 2009, 64 (11) :748-751
[7]  
JAIN RK, 1987, CANCER RES, V47, P3039
[8]   Development and evaluation of nitrendipine loaded solid lipid nanoparticles: Influence of wax and glyceride lipids on plasma pharmacokinetics [J].
Kumar, Venishetty Vinay ;
Chandrasekar, Durairaj ;
Ramakrishna, Sistla ;
Kishan, Veerabrahma ;
Rao, Yamsani Madhusudan ;
Diwan, Prakash Vamanrao .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2007, 335 (1-2) :167-175
[9]   Pharmacokinetic and pharmacodynamic evaluation of a novel in situ forming poly(ethylene glycol)-based hydrogel for the controlled delivery of the camptothecins [J].
Lalloo, Anita ;
Chao, Piyun ;
Hu, Peidi ;
Stein, Stanley ;
Sinko, Patick J. .
JOURNAL OF CONTROLLED RELEASE, 2006, 112 (03) :333-342
[10]   Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel [J].
Miglietta, A ;
Cavalli, R ;
Bocca, C ;
Gabriel, L ;
Gasco, MR .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 210 (1-2) :61-67